Retraction: Proline-rich tyrosine kinase 2 (PYK2) regulates IGF-I-induced cell motility and invasion of urothelial carcinoma cells (PLoS ONE (2012) 7: 6 (e40148) DOI: 10.1371/journal.pone.0040148);Proline-rich tyrosine kinase 2 (Pyk2) regulates IGF-I-induced cell motility and invasion of urothelial carcinoma cells

PLoS ONE

Volumn 7, Issue 6, 2012, Pages

  Genua, Marco ^a   Xu, Shi Qiong ^a   Buraschi, Simone ^a   Peiper, Stephen C ^a   Gomella, Leonard G ^a   Belfiore, Antonino ^b   Iozzo, Renato V ^a   Morrione, Andrea ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

FOCAL ADHESION KINASE 1; FOCAL ADHESION KINASE 2; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; SOMATOMEDIN C RECEPTOR;

ARTICLE; BLADDER CANCER; CANCER GROWTH; CANCER INVASION; CELL INVASION; CELL MOTILITY; CONFOCAL MICROSCOPY; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME REGULATION; GENE OVEREXPRESSION; GENE TRANSLOCATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE; IMMUNOPRECIPITATION; PHENOTYPE; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; TRANSITIONAL CELL CARCINOMA; UPREGULATION;

EID: 84862978950     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0215889     Document Type: Erratum

References (50)

1. Siegel R, Naishadham D, Jemal A, (2012) Cancer statistics, 2012. CA: A Cancer Journal for Clinicians 62: 10-29.
2. Mitra AP, Cote RJ, (2009) Molecular Pathogenesis and Diagnostics of Bladder Cancer. Annu Rev Pathol 4: 251-285.
3. Knowles MA, (2008) Molecular pathogenesis of bladder cancer. Int J Clin Oncol 13: 287-297.
4. Goebell PJ, Knowles MA, (2010) Bladder cancer or bladder cancers? Genetically distinct malignant conditions of the urothelium. Urol Oncol 28: 409-428.
5. Scher CD, Stone ME, Stiles CD, (1979) Platelet-derived growth factor prevents G0 growth arrest. Nature 281: 390-392.
6. Baserga R, (1995) The insulin-like growth factor I receptor: a key to tumor growth? Cancer Res 55: 249-252.
7. Baker J, Liu JP, Robertson EJ, Efstratiadis A, (1993) Role of insulin-like growth factors in embryonic and postnatal growth. Cell 75: 73-82.
8. Eggenschwiler J, Ludwig T, Fisher P, Leighton PA, Tilghman SM, et al. (1997) Mouse mutant embryos overexpressing IGF-II exhibit phenotypic features of the Beckwith-Wiedemann and Simpson-Golabi-Behmel syndromes. Genes Dev 11: 3128-3142.
9. Sell C, Dumenil G, Deveaud C, Miura M, Coppola D, et al. (1994) Effect of a null mutation of the insulin-like growth factor I receptor gene on growth and transformation of mouse embryo fibroblasts. Mol Cell Biol 14: 3604-3612.
10. Surmacz E, (2003) Growth factor receptors as therapeutic targets: strategies to inhibit the insulin-like growth factor I receptor. Oncogene 22: 6589-6597.
11. Baserga R, Morrione A, (1999) Differentiation and malignant transformation: two roads diverged in a wood. J Cell Biochem 75: 68-75.
12. Pollak MN, Schernhammer ES, Hankinson SE, (2004) Insulin-like growth factors and neoplasia. Nat Rev Cancer 4: 505-518.
13. Le Roith D, Karas M, Yakar S, Qu BH, Wu Y, et al. (1999) The role of the insulin-like growth factors in cancer. Isr Med Assoc J 1: 25-30.
14. Baserga R, (2000) The contradictions of the insulin-like growth factor 1 receptor. Oncogene 19: 5574-5581.
15. Baserga R, Hongo A, Rubini M, Prisco M, Valentinis B, (1997) The IGF-I receptor in cell growth, transformation and apoptosis. Biochim Biophys Acta 1332: F105-126.
16. Le Roith D, (2000) Regulation of proliferation and apoptosis by the insulin-like growth factor I receptor. Growth Horm IGF Res 10 Suppl A pp. S12-13.
17. Metalli D, Lovat F, Tripodi F, Genua M, Xu SQ, et al. (2010) The insulin-like growth factor receptor I promotes motility and invasion of bladder cancer cells through Akt- and mitogen-activated protein kinase-dependent activation of paxillin. Am J Pathol 176: 2997-3006.
18. Iozzo RV, Buraschi S, Genua M, Xu SQ, Solomides CC, et al. (2011) Decorin antagonizes IGF-IR function by interfering with IGF-IR activity and attenuating downstream signaling. J Biol Chem 286: 34712-34721.
19. Lev S, Moreno H, Martinez R, Canoll P, Peles E, et al. (1995) Protein tyrosine kinase PYK2 involved in Ca(2+)-induced regulation of ion channel and MAP kinase functions. Nature 376: 737-745.
20. Yu H, Li X, Marchetto GS, Dy R, Hunter D, et al. (1996) Activation of a novel calcium-dependent protein-tyrosine kinase. Correlation with c-Jun N-terminal kinase but not mitogen-activated protein kinase activation. J Biol Chem 271: 29993-29998.
21. Zhao J, Guan JL, (2009) Signal transduction by focal adhesion kinase in cancer. Cancer Metastasis Rev 28: 35-49.
22. Webb DJ, Donais K, Whitmore LA, Thomas SM, Turner CE, et al. (2004) FAK-Src signalling through paxillin, ERK and MLCK regulates adhesion disassembly. Nat Cell Biol 6: 154-161.
23. Weis SM, Lim ST, Lutu-Fuga KM, Barnes LA, Chen XL, et al. (2008) Compensatory role for Pyk2 during angiogenesis in adult mice lacking endothelial cell FAK. J Cell Biol 181: 43-50.
24. Lipinsky CA, FLoftus JC, (2010) The Pyk2 FERM domain: a Novel Therapeutic Target. Expert Opin Ther Targets 14: 95-108.
25. Morrione A, Romano G, Navarro M, Reiss K, Valentinis B, et al. (2000) Insulin-like growth factor I receptor signaling in differentiation of neuronal H19-7 cells. Cancer Res 60: 2263-2272.
26. Peruzzi F, Prisco M, Dews M, Salomoni P, Grassilli E, et al. (1999) Multiple signaling pathways of the insulin-like growth factor 1 receptor in protection from apoptosis. Mol Cell Biol 19: 7203-7215.
27. Peruzzi F, Prisco M, Morrione A, Valentinis B, Baserga R, (2001) Anti-apoptotic signaling of the insulin-like growth factor-I receptor through mitochondrial translocation of c-Raf and Nedd4. J Biol Chem 276: 25990-25996.
28. Rubin MA, Zerkowski MP, Camp RL, Kuefer R, Hofer MD, et al. (2004) Quantitative determination of expression of the prostate cancer protein alpha-methylacyl-CoA racemase using automated quantitative analysis (AQUA): a novel paradigm for automated and continuous biomarker measurements. Am J Pathol 164: 831-840.
29. Schaller MD, (2010) Cellular functions of FAK kinases: insight into molecular mechanisms and novel functions. J Cell Sci 123: 1007-1013.
30. Pylayeva Y, Gillen KM, Gerald W, Beggs HE, Reichardt LF, et al. (2009) Ras- and PI3K-dependent breast tumorigenesis in mice and humans requires focal adhesion kinase signaling. J Clin Invest 119: 252-266.
31. Guo W, Giancotti FG, (2004) Integrin signalling during tumour progression. Nat Rev Mol Cell Biol 5: 816-826.
32. Bao W, Stromblad S, (2004) Integrin alphav-mediated inactivation of p53 controls a MEK1-dependent melanoma cell survival pathway in three-dimensional collagen. J Cell Biol 167: 745-756.
33. Valentinis B, Romano G, Peruzzi F, Morrione A, Prisco M, et al. (1999) Growth and differentiation signals by the insulin-like growth factor 1 receptor in hemopoietic cells are mediated through different pathways. J Biol Chem 274: 12423-12430.
34. Valentinis B, Navarro M, Zanocco-Marani T, Edmonds P, McCormick J, et al. (2000) Insulin receptor substrate-1, p70S6K, and cell size in transformation and differentiation of hemopoietic cells. J Biol Chem 275: 25451-25459.
35. Morrione A, Navarro M, Romano G, Dews M, Reiss K, et al. (2001) The role of the insulin receptor substrate-1 in the differentiation of rat hippocampal neuronal cells. Oncogene 20: 4842-4852.
36. Dews M, Prisco M, Peruzzi F, Romano G, Morrione A, et al. (2000) Domains of the insulin-like growth factor I receptor required for the activation of extracellular signal-regulated kinases. Endocrinology 141: 1289-1300.
37. Shen X, Xi G, Radhakrishnan Y, Clemmons DR, (2010) Recruitment of Pyk2 to SHPS-1 signaling complex is required for IGF-I-dependent mitogenic signaling in vascular smooth muscle cells. Cell Mol Life Sci 67: 3893-3903.
38. Farshori PQ, Shah BH, Arora KK, Martinez-Fuentes A, Catt KJ, (2003) Activation and nuclear translocation of PKCdelta, Pyk2 and ERK1/2 by gonadotropin releasing hormone in HEK293 cells. J Steroid Biochem 85: 337-347.
39. Aoto H, Sasaki H, Ishino M, Sasaki T, (2002) Nuclear translocation of cell adhesion kinase beta/proline-rich tyrosine kinase 2. Cell Struct Funct 27: 47-61.
40. Lassak A, Del Valle L, Peruzzi F, Wang JY, Enam S, et al. (2002) Insulin receptor substrate 1 translocation to the nucleus by the human JC virus T-antigen. J Biol Chem 277: 17231-17238.
41. Wu A, Sciacca L, Baserga R, (2003) Nuclear translocation of insulin receptor substrate-1 by the insulin receptor in mouse embryo fibroblasts. Journal of Cellular Physiology 195: 453-460.
42. Sun H, Tu X, Prisco M, Wu A, Casiburi I, et al. (2003) Insulin-like growth factor I receptor signaling and nuclear translocation of insulin receptor substrates 1 and 2. Molecular Endocrinology 17: 472-486.
43. Reiss K, Del Valle L, Lassak A, Trojanek J, (2011) Nuclear IRS-1 and cancer. J Cell Physiol 227: 2992-3000.
44. Wu A, Chen J, Baserga R, (2008) Nuclear insulin receptor substrate-1 activates promoters of cell cycle progression genes. Oncogene 27: 397-403.
45. Migliaccio I, Wu MF, Gutierrez C, Malorni L, Mohsin SK, et al. (2010) Nuclear IRS-1 predicts tamoxifen response in patients with early breast cancer. Breast Cancer Res Treat 123: 651-660.
46. Monami G, Emiliozzi V, Bitto A, Lovat F, Xu SQ, et al. (2009) Proepithelin regulates prostate cancer cell biology by promoting cell growth, migration, and anchorage-independent growth. Am J Pathol 174: 1037-1047.
47. Lovat F, Bitto A, Xu SQ, Fassan M, Goldoni S, et al. (2009) Proepithelin is an autocrine growth factor for bladder cancer. Carcinogenesis 30: 861-868.
48. Monami G, Emiliozzi V, Morrione A, (2008) Grb10/Nedd4-mediated multiubiquitination of the insulin-like growth factor receptor regulates receptor internalization. J Cell Physiol 216: 426-437.
49. Monami G, Gonzalez EM, Hellman M, Gomella LG, Baffa R, et al. (2006) Proepithelin promotes migration and invasion of 5637 bladder cancer cells through the activation of ERK1/2 and the formation of a paxillin/FAK/ERK complex. Cancer Res 66: 7103-7110.
50. Buraschi S, Pal N, Tyler-Rubinstein N, Owens RT, Neill T, et al. (2010) Decorin antagonizes Met receptor activity and down-regulates {beta}-catenin and Myc levels. J Biol Chem 285: 42075-42085.